中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2018-09-10

Important News! Henlius Combination Therapy Received Approval to Conduct Clinical Trials in China
2018-08-09

Henlius Submitted Investigational New Drug Application for Its HLX12
2018-06-21

Henlius and Accord Entered into an License Agreement for HLX02
2018-06-04

Henlius will Initiate Phase I Clinical Trialof HLX20 (Anti-PD-L1 Antibody) in Australia
2018-05-24

Important News! Henlius Completed Its First Phase III Study of HLX01(Rituximab Injection)
2018-05-22

Henlius Formed Scientific Advisory Board (SAB)
2018-05-10

China's Global Investment Push Opens Doors for Domestic Biotechs
2018-03-01

Hail! Shanghai Henlius Biotech, Inc. is Honored as the Annual Preeminence of Asia Biotech of 2017
2018-01-22

Innovation-driven Development | Market Capitalization of Henlius Biotech Hits CNY 10 Billion